News

Researchers identify new way to attack herpesviruses

Kate O'Rourke
By Kate O'Rourke
Jan. 30, 2022

new study published this week in the journal mBio has opened the door to a new approach to attacking herpesviruses. The study demonstrated that targeting two metal ion-dependent enzymes of human herpesviruses with two compounds can inhibit the replication of the virus. The finding provides new opportunities to developing agents against herpesviruses. 

“A lot of people know the herpes simplex viruses, but there is actually a family of 9 different herpesviruses including cytomegalovirus (CMV) which causes a lot of problems for immunocompromised people, folks getting transplants and chemotherapy patients for example. We need better therapeutic agents that can be used in these very vulnerable populations,” said co-author of the study Dennis Wright, professor of medicinal chemistry in the School of Pharmacy at the University of Connecticut. “Right now, the therapeutic agents that are out there aren’t terribly effective in terms of being able to treat all the viruses, and many of them have a significant dose-limiting toxicities and associated side effects."  

Ideally, said Wright, there would be one drug that would inhibit the reactivation of all nine herpesviruses. Co-study author Sandra K. Weller, a distinguished professor of molecular biology and biophysics in the School of Medicine at the University of Connecticut, identified targets that would allow just that. She identified herpesvirus enzymes that require two magnesiums for the herpesvirus to replicate.

“The majority of drug discovery efforts against herpesviruses has focused on nucleoside analogs that target viral DNA polymerases. We are pursuing a strategy based on targeting two-metal-ion-dependent viral enzymes,” said Weller. 

The researchers tested the ability of a panel of compounds to inhibit specific two metal ion-dependent enzymes as well as herpesvirus replication. The panel of compounds tested included HIV integrase inhibitors, the anti-influenza agent baloxavir, 3 natural products previously shown to exhibit anti-herpes simplex virus activity, and two 8-hydroxyquinolones, AK-157 and AK-166. 

While HIV integrase inhibitors have been reported to inhibit replication of herpesviruses, the researchers found the integrase inhibitors exhibited weak overall anti-HSV-1 activity.  However, the researchers found that 8-hydroxyquinolones displayed strong antiviral activity against both HSV-1 and CMV and could inhibit one or more of the two metal ion dependent enzymes.  This opens up the possibility of potentially developing dual targeting agents against herpesviruses.  

This article was adapted from a press release by the American Society for Microbiology. It has been edited for style.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Kate O'Rourke
Kate O'Rourke

Kate O'Rourke is a freelance science writer living in Portland, Maine. She has been writing about science and human and animal health for over 20 years.
 

Related articles

Finding a way to combat long COVID
Marissa Locke Rottinghaus
Structure of the key protein for an HCV vaccine
Lisa Eshun–Wilson & Alba Torrents de la Peña

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

 A new kind of stem cell is revolutionizing regenerative medicine
Feature

A new kind of stem cell is revolutionizing regenerative medicine

April 1, 2025

Induced pluripotent stem cells are paving the way for personalized treatments to diabetes, vision loss and more. However, scientists still face hurdles such as strict regulations, scalability, cell longevity and immune rejection.

Engineering the future with synthetic biology
ASBMB Annual Meeting

Engineering the future with synthetic biology

March 31, 2025

Learn about the ASBMB 2025 symposium on synthetic biology, featuring applications to better human and environmental health.

Scientists find bacterial ‘Achilles’ heel’ to combat antibiotic resistance
Webinar

Scientists find bacterial ‘Achilles’ heel’ to combat antibiotic resistance

March 28, 2025

Alejandro Vila, an ASBMB Breakthroughs speaker, discussed his work on metallo-β-lactamase enzymes and their dependence on zinc.

Host vs. pathogen and the molecular arms race
ASBMB Annual Meeting

Host vs. pathogen and the molecular arms race

March 28, 2025

Learn about the ASBMB 2025 symposium on host–pathogen interactions, to be held Sunday, April 13 at 1:50 p.m.

Richard Silverman to speak at ASBMB 2025
ASBMB Annual Meeting

Richard Silverman to speak at ASBMB 2025

March 27, 2025

Richard Silverman and Melissa Moore are the featured speakers at the ASBMB annual meeting to be held April 12-15 in Chicago.

From the Journals: JBC
Journal News

From the Journals: JBC

March 25, 2025

How cells recover from stress. Cancer cells need cysteine to proliferate. Method to make small membrane proteins. Read about papers on these topics recently published in the Journal of Biological Chemistry.